Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge
06:42pm, Monday, 11'th Jul 2022 Benzinga
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June.
The Dow traded down 0.30% to 31,242.86 while the NASDAQ fell 1.85% to 11,419.99.
Why Pliant Therapeutics Stock Is Crushing It Today
04:57pm, Monday, 11'th Jul 2022 The Motley Fool
A positive mid-stage trial readout in idiopathic pulmonary fibrosis is powering the biotech's stock higher.
Nasdaq Tumbles 2%; Pliant Therapeutics Shares Spike Higher
04:41pm, Monday, 11'th Jul 2022 Benzinga
U.S. stocks traded lower midway through trading following the release of jobs report on Friday.
The Dow traded down 0.50% to 31,180.09 while the NASDAQ fell 2.08% to 11,392.80. The S&P also fell, drop
After-Hours Alert: Why Pliant Therapeutics Stock Is Moving
04:32pm, Monday, 11'th Jul 2022
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are volatile in Monday's after-hours session after the company announced a proposed $150 million offering. Pliant Therapeutics shares soared by nearly 1
Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session
04:11pm, Monday, 11'th Jul 2022 Benzinga
Gainers
Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study.
La Jolla Pharm
Why U.S. Stocks Are Trading Lower; AZZ Earnings And More
02:55pm, Monday, 11'th Jul 2022 Benzinga
U.S. stocks traded lower this morning as investors digested the recent jobs report for the month of June.
The Dow traded down 0.38% to 31,220.54 while the NASDAQ fell 1.67% to 11,441.36. The S&P also
Why Pliant Therapeutics Stock Is Crushing It Today
12:57pm, Monday, 11'th Jul 2022
A positive mid-stage trial readout in idiopathic pulmonary fibrosis is powering the biotech's stock higher.
Why Is Twitter Down By More Than 5%? 22 Stocks Moving In Monday's Pre-Market Session
11:26am, Monday, 11'th Jul 2022 Benzinga
Gainers
Inpixon (NASDAQ: INPX) rose 25.8% to $0.2305 in pre-market trading after gaining more than 22% on Friday.
Nyxoah S.A. (NASDAQ: NYXH) rose 25.3% to $10.02 in pre-market trading after the compa
Why Is Pliant Therapeutics (PLRX) Stock Soaring Today?
10:30am, Monday, 11'th Jul 2022
Pliant Therapeutics (PLRX) stock is rocketing higher on Monday after revealing data from a Phase 2 clinical trial of PLN-74809. The post Why Is Pliant Therapeutics (PLRX) Stock Soaring Today?
Pliant Therapeutics (PLRX) Stock: Why It Skyrocketed Over 60% Today
09:01am, Monday, 11'th Jul 2022
The stock price of Pliant Therapeutics Inc (NASDAQ: PLRX) skyrocketed over 60% pre-market today. This is why.
Why Are Pliant Therapeutics Shares Rallying Today?
08:33am, Monday, 11'th Jul 2022
Pliant Therapeutics Inc's (NASDAQ: PLRX) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and secondary endpoints. The data demonstrated that PLN-7480
Pliant Therapeutics: Analysts' Favorite
08:58pm, Thursday, 23'rd Jun 2022
14 new highs and up 68.36% in the last month. Price target of $38.00 to as high as $51.00.
Pliant: Major Catalyst Expected Beginning Of 2023
06:26pm, Friday, 03'rd Jun 2022
Results from the phase 2a INTEGRIS-PSC study using PLN-74809 for the treatment of patients with primary sclerosing cholangitis are expected 1st half of 2023. PLN-74809 is also being explored for the t
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022
02:13pm, Wednesday, 25'th May 2022 Benzinga
Upgrades
Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of
Pliant Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 11'th May 2022
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics
